Privia Health Group, Inc. (PRVA)

Over the past six months, Privia Health Group's stock has seen a return of +16.7%, but declined 11.1% in the last three months. A sector-wide concern in late January 2026, due to UnitedHealth Group's warning, put pressure on PRVA. Despite this, Privia Health reported better-than-expected revenue in Q3 CY2025, with sales up 32.5% year-on-year to $580.4 million, and a non-GAAP profit of $0.29 per share. Following these results, Privia Health's stock rose 7.31% in pre-market trading. The company is scheduled to report its Q4 2025 results on February 26, 2026.

While specific demand seasonality for Privia Health Group's products and services is not explicitly detailed, the broader healthcare sector exhibits seasonal trends, with the largest proportion of annual patient payments occurring in March and the second quarter. Privia Health's financial performance could be indirectly influenced by these broader healthcare payment cycles.

Privia Health Group, Inc. is a national physician-enablement company that empowers physicians to optimize their practices, enhance patient experiences, and transition to value-based care models. They offer technology and population health tools, a management services organization (MSO), and a single-TIN medical group. Their cloud-based Privia Technology Solution integrates EHR, telehealth, patient portals, and analytics. Privia also operates Accountable Care Organizations (ACOs) to engage patients, reduce unnecessary utilization, and improve care coordination. As of 2023, Privia managed ten ACOs serving approximately 198,000 Medicare beneficiaries. The company's revenue model includes fee-for-service patient care, administrative services, and value-based care arrangements.

Privia Health operates in 13 states and the District of Columbia, supporting over 5,200 providers across more than 1,300 practice locations. Their services extend to beneficiaries in states such as California, Connecticut, Delaware, Florida, Georgia, Maryland, Montana, North Carolina, Tennessee, Texas, and Virginia.

Privia Health Group generally maintains a positive brand reputation, with a consensus rating of "Moderate Buy" and a projected upside of approximately 38.7% from its current price. In Q3 2025, Privia Health was identified as a top performer among healthcare technology providers. However, some concerns have been raised by private practice doctors regarding potential extra fees, billing problems with their system (Athena EHR), and the inclusion of a "first right of refusal" clause.

Approximately 94.48% of Privia Health Group's stock is held by institutions, while insiders hold 10.70%. Major institutional shareholders include BlackRock, Inc., Fmr Llc, Vanguard Group Inc, Durable Capital Partners LP, Rubicon Founders LLC, Riverbridge Partners Llc, State Street Corp, and Van Berkom & Associates Inc. In the past three months, company insiders have sold more of their stock than they have bought, with sales totaling $939,203.00 and no reported purchases.